Skip Navigation

Your Environment. Your Health.

B cell depletion in Idiopathic Inflammatory Myopathy

Principal Investigator:

Jo Edwards, Shabina Sultan, David Isenberg, University College, London

Study Design:

Phase 1 open, at University College, London

Types & Number of IIM Studied:

Active Polymyositis or Dermatomyositis (N = 5)

Entry Criteria:

Definite Polymyositis or Dermatomyositis by Bohan and Peter criteria; Refractory to standard therapy

IMACS Core Set Measures Included:

MITAX, Physician and Patient Global Activity Assessment, Manual Muscle Testing (MMT-8), Health Assessment Questionnaire, muscle enzymes; Health Related Quality of Life by SF-36

Other Measures Included:

Myometry, Activities of Daily Living, rash, B cells, serology

Primary Outcome:

Myometry and Creatine kinase

Study Duration:

6 months


Myositis Support Group UK


Study has completed enrollment


Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy., Rheumatology(Oxford), 2008 Sep;47(9):1379-83. [Abstract]


David A. Isenberg , M.D., F.R.C.P., M.D.
ARC Diamond Jubilee Professor of Rheumatology
University College London
Centre for Rheumatology, University College London
Arthur Stanley House
40-50 Tottenham Street
London W1P 9PG UK

Return to Studies in the Repository listing